Aerpio. good year-end share to conference of I very financial and call our for morning. on to is This Thank President Welcome XXXX Joseph today's you plan excited Aerpio results. am XXXX Aerpio's with Pharmaceuticals. you, Gardner, Gina,
announced plan value. October, efforts. alternatives the maximize continue various As strategic to exploring we We to are in these company shareholder
also leaders, which in we we investigators a However, ocular readout XXXX. received AKB-XXXX a to Phase II opinion trial expect key first the of feedback from have in and glaucoma, decided in light we to of prescribers, topical have of data of quarter the conduct formulation strong
a of $XX.X very XXXX. this and XX, support to cash as of million cash in strong financial is December equivalents program Aerpio Fortunately, position with
recall XX top a in cohort a XX of was day of I of reduction glaucoma millimeters line or X.XX announced to patients added that intraocular In we AKB-XXXX millimeter Please prostaglandin incremental of saw Ib here. treatment. will glaucoma we IOP, daily trial from January, it X mercury Phase when on baseline data once ranging with on in IOP briefly AKB-XXXX diurnal pressure, from a a recap standard-of-care top XX mercury, but of in existing
statistically in also sequential saw via with data baseline. previously and the show statistically ocular outflow TieX significant discoveries previous In activation increased studies in consistent a lowered neurointensive AKB-XXXX of about systemically of mechanism measured IOP the resistance at reported IOP time decreasing in lowering are from with improvements and X II all canal the points These we signal, which Phase eye, retinopathy. after dosed in of fact, we IOP patients action diabetic to saw our which Schlemm's AKB-XXXX, significant
placebo significant is on produced experts, to both glaucoma with preclinical to the that extensive in be in drops very compared therapy external data prostaglandin data statistically completed and reductions encouraging feedback and the AKB-XXXX of scientific these on top clinical Based recently Ib and from subjects. believe Phase drug critical promising. topical we baseline when point out The piece against IOP standard-of-care of
of drug therapy. best-in-class profile candidate, favorable clinically no meaningful, which suggests a incidence effects important, for these systemic market. a differentiator hypovolemia clear today's but also that tolerability clinical for in adjunctive suggested advisers low data were is safety Our and the Equally topical only potentially of the including magnitude a concerns, a not
study or We competing moving with into is Ib drug a the better efficacy differentiated data better than tolerability profile. believe Our products forward develop distinguished Phase a that to support objective equal in by is a also to glaucoma confirm Phase be these glaucoma to in Phase intend which XX-day a II duration, of clinical of design recently longer results approved encouraging agents. to line with in we trials study II
to after cash significant data reporting have and available We the a runway in early top study sufficient line provide support XXXX.
is glaucoma that important We believe an opportunity.
cause is loss. you intraocular affecting fluid neuropathy is million removes resistance represents have It is Multiple pressure by a is in serious know, trabecular that main the shown vision of slows front in IOP. optic the of outflow drain caused is tone that of of Increased IOP pathway eye. IOP increased patients glaucoma X.X the the lowering the associated of increased canal of to leading contractual The condition of in many from or progression conventional and a longitudinal eye, worldwide. progressive As blindness increased Glaucoma glaucoma meshwork Schlemm's outflow a studies that in canal. changes U.S. conductance due conventional the the and Schlemm's with stiffness
the production. glaucoma topical The the older and beta-blockers, outflow uveoscleral like outflow alpha carbonic anhydrase eyedrops used drugs conventional do the and not pathway. Prostaglandin fluid increase most reduce of analogues pathology drainage drugs pathway. inhibitors are address widely the agonists via And
pathway none Schlemm's tolerable if the once-daily, conventional However, to AKB-XXXX, approved, therapy as which for as a be commercial in specifically attractive sets drugs opportunity outflow eye drop large adjunctive these extremely target a we in up an of used potentially canal, believe market.
the represent in for become therapy. the estimated at as is market AKB-XXXX per for over year currently Schlemm's potential published segment either conjunction That Drugs Based glaucoma $X.X glaucoma. the has adjuvant science, TieX use that of billion billion $X the market. on therapy the canal, or role glaucoma first global in in the of disease-modifying to supporting the we believe of combinations, maintenance with of therapy roughly XX% fixed-dose prostaglandins,
to very enthusiastic for glaucoma, are we opportunity AKB-XXXX repeat this shareholders. therapy that. about We become potential me for first our Let has and the disease-modifying believe the
expect this patients year. of for the the We third dosing initiate to quarter trial Phase II of in of planned AKB-XXXX
glaucoma molecule opportunity, Now by I to our TieX field assets in TieX of in continue activators both strategic pioneered and we Schlemm's also activation small the to activate in of vascular importantly, uniquely and antibody drug is cells tyrosine addition vasculature, of want receptor to alternatives. other that the pipeline eye. kinase, TieX expressed summarize explore endothelial Aerpio and in for also which expressed is canal developing front the the a has candidates TieX. in all
settings, by our years have diabetic stabilizes demonstrated to potential publications. in activation over pathology where the TieX variety TieX to These by activators vasculature include nephropathy underlying Aerpio's have glaucoma. learned driven We that unstable of diseases multiple the vessels. is addition diseases in treat a as the
The XX%. completed suggests creatinine previous In decreasing to IIb decrease about TieX the in other ratio by dialysis. by may TIME-Xb, proteinuria a urinary a we measured this recently the our result AKB-XXXX, activating AKB-XXXX progression kidney study, diabetics, demonstrated have kidney ARP-XXXX, Phase study. as in that had albumin and Phase ability potentially potential replicated drug, that proteinuria, the lower And to function found improve delaying II in to
a receptors manner ARP-XXXX asset, treat TieX therapy second in monthly The ARP-XXXX a preclinical dose-dependent monoclonal nephropathy. models. activate a to in observed including systemic is or a antibody, diabetic to potential diabetic believes holds company's Aerpio biweekly humanized complications, as the
is third that activation a bispecific company's and and current has antibodies to The product binds edema. macular antibody be which activates wet VE-PTP, improved This asset a as These the inhibits VEGF and would bispecific age-related treating an and the potential both TieX. VEGF macular antibody into intravitreally EYLEA degeneration diabetic for LUCENTIS. drugs in anti-VEGF like the eye same fashion dosed be
trial. currently sales terms partner, is of is of related candidate a the this upon Phase as if now is receive product, activator of to commercialized. TieX fourth asset, net to Ib developed Lastly, and Gossamer, for that agreement, hypoxia-inducible that which has ulcerative has eligible is the a not drug activation. GBXXX, and is the company by satisfaction approved payments a colitis being Aerpio royalties factor completed upon AKB-XXXX, it milestones known The our and Under
We during you attention your thank this for call.
for company. transformative could our glaucoma are to back Marek. Aerpio of turn call the excited Gina and program over the VP believe the now Finance, be about We will prospects very for I that our
